Evidence map›Paper›PMID 31665941›Full record

ReviewExpert review of anticancer therapy2019

The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib.

Christopher P Wilding, Mark L Elms, Ian Judson, Aik-Choon Tan, Robin L Jones, Paul H Huang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert review of anticancer therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Christopher P WildingDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.
Mark L ElmsDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.
Ian JudsonDepartment of Medical Oncology, Sarcoma Unit, The Royal Marsden Hospital, London, UK.
Aik-Choon TanDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, USA.
Robin L JonesDepartment of Medical Oncology, Sarcoma Unit, The Royal Marsden Hospital, London, UK.
Paul H HuangDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug Resistance, NeoplasmHumansIndazolesPrecision MedicineProtein Kinase InhibitorsProtein-Tyrosine KinasesPyrimidinesSarcomaSulfonamidesIndazolespazopanibProtein Kinase InhibitorsProtein-Tyrosine KinasesPyrimidinesSulfonamidesbiomarkerskinasessarcomassignal transductiontargeted therapytyrosine kinase inhibitors

Identifiers

PMID31665941
PMCPMC6882314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.